Overview
The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2026-06-01
2026-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective of the PERI-STEMI trial is to assess whether sacubitril-valsartan is more effective in preventing adverse LV remodeling for patients with ST-elevation myocardial infarction (STEMI) than enalapril.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
West China HospitalTreatments:
Enalapril
LCZ 696
Sacubitril and valsartan sodium hydrate drug combination
Valsartan
Criteria
Inclusion Criteria:- Aged between 18 - 75 years old
- First-time ST-segment elevation myocardial infarction based on the newest ESC
guidelines
- Timely primary percutaneous coronary intervention within 12 hours from onset
- Written informed consent acquired
Exclusion Criteria:
- Known history of or persistent clinical chronic heart failure prior to randomization
- Previous use of ARNI, or intolerance or contraindications to study drugs including
ARNI or ACEI
- History of significant chronic coronary obstruction and adverse ventricular remodeling
- History of any cardiomyopathy, valvular heart disease, congenital heart disease, stent
or CABG, or planned open-heart surgery within 3 months
- History of hepatic impairment or history of cirrhosis with evidence of portal
hypertension
- History of chronic renal dysfunction, or eGFR < 30 ml/min/1.73 m2
- History of malignancy and with a life span less than one year
- Patients with a known history of angioedema related to previous ACEIs/ARB therapy.
- With contraindication to MRI examination (pacemaker and claustrophobia) or cannot
finish breath-holding when lying on the examination bed
- Pregnancy or nursing women